Teva Pharmaceuticals UK - Search News

Alvotech, Teva Pharmaceuticals and FDA

Seeking Alpha on MSN · 19h

Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application for AVT06. Read more here.

Business Insider · 23h

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also holds commercialization rights for AVT29 in the U.S.

Investopedia on MSN · 18h

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron Pharmaceuticals’ Eylea.

The Teva Turnaround: Steering a Company Comeback

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

14hon MSN

Teva share price struggles to recover following $6 billion market loss

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

12d

Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...

2don MSN

Teva Pharm CEO calls for faster US generic drug approvals

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

BioPharma Dive8d

Axsome secures top drug’s future with Teva patent settlement

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

The Pharma Letter9d

Medincell wins milestone from Teva on back of SOLARIS trial

France-based biopharma company Medincell this morning revealed it is to receive a $5 million development milestone from ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results